AES

Arqit, BT, and Fortinet Launch Quantum-Safe VPN to Protect Against Evolving Cyberthreats

Retrieved on: 
Thursday, December 14, 2023
NCSC, Citizenship, Risk, GSMA, Confidentiality, United States Congress, AES, PKC, NSA, Congress, VPN, Quantum computing, National Security Agency, IP, Fortinet, NSS, BT Group, HAIPE, EVP, Cryptocurrency

This announcement follows the successful trial of quantum-safe tunnels between three BT sites in London, Exeter, and Adastral Park in Suffolk.

Key Points: 
  • This announcement follows the successful trial of quantum-safe tunnels between three BT sites in London, Exeter, and Adastral Park in Suffolk.
  • As cyberthreats evolve and become increasingly sophisticated, organisations worldwide need to ensure they can defend their data and communications against both existing and upcoming threats.
  • The solution provides quantum-safe symmetric keys that can be created and rotated on-demand to encrypt and protect sensitive data between point-to-point VPN links.
  • By integrating our cloud-based software into Fortinet firewalls, combined with a BT managed service, we've made this an easy step for organisations already using Fortinet solutions.

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)

Retrieved on: 
Saturday, December 2, 2023
Xenon, Quality of life, Skill, SCN1A, Convention, Aes, Efficacy, Depression, Epilepsy, AES, Poster, American Epilepsy Society, ASMS, DSM-IV codes, SFG, Seizure, MPC, Dravet syndrome, Anxiety, Annual general meeting, Neurology, Food, Safety, MDD, Patient, Orange County Convention Center, OLE, Pharmaceutical industry

VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023).

Key Points: 
  • VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023).
  • Importantly, we are looking forward to presenting new interim data from our ongoing open-label extension study from our Phase 2b X-TOLE trial.
  • The exhibit will also feature the topline results from the Phase 2 proof-of-concept X-NOVA clinical trial in major depressive disorder.
  • Posters will be added to the Xenon website consistent with AES 2023 conference guidelines.

NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting

Retrieved on: 
Friday, December 1, 2023
Responsive neurostimulation device, Epilepsy, Generalization, LGS, AES, Hemispherectomy, IGE, Patient, RCT

“The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.

Key Points: 
  • “The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.
  • “We look forward to collaborating with the many healthcare providers, scientists, and others from all over the world who are gathering in Orlando to promote better outcomes for people with epilepsy.
  • We will host various presentations and events highlighting our RNS System and look forward to engaging with the broader scientific community in the epilepsy field.”
    Over 50 original scientific presentations and posters regarding the RNS System will be presented throughout the meeting, as well as a number of general meeting sessions that include how the RNS System provides an important therapy option for the treatment of drug resistant epilepsy.
  • These presentations, posters, and events involve key opinion leaders as well as early career scientists and clinicians, all of whom aim to improve the lives of patients living with drug-resistant epilepsy.

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Retrieved on: 
Friday, December 1, 2023
Neuroprotection, Benzodiazepine, Temporal lobe epilepsy, Kainic acid, Brain, KCC2, AES, American Epilepsy Society, Seizure, PD, Annual general meeting, Epilepsy, Dentate gyrus, Patient, DSM-IV codes, Pharmaceutical industry

and Chief Medical Officer of Ovid Therapeutics.

Key Points: 
  • and Chief Medical Officer of Ovid Therapeutics.
  • “GABA-AT is a validated target in seizure reduction that has been limited in clinical use to date.
  • Title: Blocking of GABA-AT Activity by OV329 Selectively Alters Tonic and Phasic Inhibition in Dentate Gyrus Granule Cells.
  • Title: Low, Repeat Dosing of OV329 Enhances GABA-AT Inhibition in Rodent Brain: Relationship between Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects.

Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting

Retrieved on: 
Friday, December 1, 2023
Generalized tonic–clonic seizure, PO, Risk, Epilepsy, AES, American Epilepsy Society, Therapy, Human, GABAA, FAAN, DSM-IV codes, Patient, Safety, Pharmacology, GAERS, Pharmaceutical industry

MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.

Key Points: 
  • MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.
  • The Company's presentation details are as follows:
    “We are pleased with the progress made with BAER-101, a molecule with unique pharmacology which has demonstrated that it can significantly suppress seizures in a translational animal model of absence epilepsy,” said Alexandra MacLean, M.D., Chief Executive Officer of Avenue.
  • In the model, BAER-101 demonstrated full suppression of seizure activity with a minimal effective dose of 0.3 mg/kg, PO.
  • The combination of safety and tolerability in hundreds of patients and the preclinical efficacy data support BAER-101’s continued development in a Phase 2a trial.

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

Retrieved on: 
Friday, December 1, 2023
Patient, Conference, Hospital, Seizure, Genetic counseling, Whole genome sequencing, Epilepsy, AES, American Epilepsy Society, Diet, National Society, DSM-IV codes, MD, Doctor of Philosophy, Research, Health, NSGC, Parent, Insurance, Test management, Genetic testing, FACMG, Medicaid, Diagnosis, Clinical, WGS, Michelle, GeneDx

The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.

Key Points: 
  • The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.
  • Of those patients with a positive genetic diagnosis from exome sequencing, 11% had a variant in a treatment related gene.
  • GeneDx will also present data at the conference that shows insurance may offer better coverage for exome sequencing than multi-gene panels for patients with epilepsy.
  • At the conference, GeneDx will also be hosting an industry sponsored symposium discussing the ways in which exome sequencing can help epilepsy patients find answers sooner.

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

Retrieved on: 
Tuesday, November 28, 2023
Molecule, Clinical trial, Audiogenic, Conference, PAME, Drug discovery, EEG, SCN2A, Drug development, Cerebrum, DEE, AES, Mortality, American Epilepsy Society, SCN8A, Standard of care, Pharmacokinetics, Annual general meeting, CNS, Part, Biomarker, Family Gathering, Generalized tonic–clonic seizure, Central nervous system, Patient, Safety, BTS, ASM, MES, Pharmaceutical industry

Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.

Key Points: 
  • Presentations at the American Epilepsy Society (AES) Annual Meeting, as well as related scientific and patient advocacy meetings, will cover new patient data, updates on clinical progress and new paradigms for developing epilepsy therapies.
  • ET [Platform D | Epilepsy Therapies]
    Summary: Combined preclinical and clinical data demonstrate PRAX-628 is differentiated from standard of care, with the potential to be best-in-class for focal epilepsy.
  • Summary: This study provides novel insights into the clinical validity of commonly used preclinical seizure models across the clinical epilepsy spectrum.
  • Oral presentation highlighting clinical updates from our PRAX-562 small molecule platform at the annual clinician, researcher, and family gathering for SCN8A

AES Announces Closing of Previously Announced and New Minority Sell-Downs of LNG Businesses in the Dominican Republic and Panama

Retrieved on: 
Thursday, December 21, 2023
Power, Sale, Wind, AES, AES Corporation, Mong, Coal, DPP, Cryptocurrency

ARLINGTON, Va., Dec. 21, 2023 /PRNewswire/ -- The AES Corporation (NYSE: AES) announced today that it has closed minority sell-downs of its businesses in the Dominican Republic and its AES Colón business in Panama for proceeds of $338 million.  This includes the transactions announced in September for proceeds of $179 million after purchase price adjustments at closing, as well as sell-downs of additional stakes in the businesses through the expansion of existing partnerships with Grupo Estrella and Grupo Popular's subsidiary, AFI Popular, through one of its closed-end funds, for $159 million.  In total, AES sold 20% of its businesses in the Dominican Republic and 35% of AES Colón in Panama.

Key Points: 
  • ARLINGTON, Va., Dec. 21, 2023 /PRNewswire/ -- The AES Corporation (NYSE: AES) announced today that it has closed minority sell-downs of its businesses in the Dominican Republic and its AES Colón business in Panama for proceeds of $338 million.
  • In total, AES sold 20% of its businesses in the Dominican Republic and 35% of AES Colón in Panama.
  • "These transactions include the closing of the two previously announced sell-downs, as well as the sale of an additional 10% in the Dominican Republic and an additional 15% of AES Colón in Panama."
  • AES will continue operating its businesses in the Dominican Republic and Panama, with an ownership interest of 65% in each business.

iFLYTEK is Taking New Strides in Global Development with Successful Listing and Sales in Singapore and Participation in Indonesian AES

Retrieved on: 
Monday, December 18, 2023
Appliance, Research, AES, Court, AI, Exhibition, Intelligence, Renewable energy

Additionally, iFLYTEK participated in the Appliances & Electronics Show (AES), a significant exhibition event in Indonesia, marking another pivotal advancement in implementing its global strategy.

Key Points: 
  • Additionally, iFLYTEK participated in the Appliances & Electronics Show (AES), a significant exhibition event in Indonesia, marking another pivotal advancement in implementing its global strategy.
  • iFLYTEK's global strategy is focused on growing its presence in promising Southeast Asia markets, including Singapore and Indonesia.
  • Concurrently, iFLYTEK participated in AES, showcasing a range of smart hardware products that earned the prestigious Most Innovative Award.
  • iFLYTEK remains steadfast in its commitment to innovative research and development in artificial intelligence, coupled with the expansion of global partnerships.

Fluence Energy, Inc. Announces Executive Transition

Retrieved on: 
Thursday, November 16, 2023
AES Corporation, NYSE, Treasury, Bank statement, PIN, Adjusted gross income, GAAP, Adjustment, News, EST, Growth, AES, Cryptocurrency, Security (finance), Radiant exposure

ARLINGTON, Va., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a leading global provider of energy storage products and services, and optimization software for renewables and storage, today announced that Ahmed Pasha will succeed Manavendra Sial (Manu) as Senior Vice President and Chief Financial Officer of the Company, effective January 1, 2024.

Key Points: 
  • Mr. Pasha commented, “I am thrilled to join Fluence at a time when the energy transition is achieving critical momentum, which presents so much opportunity for the Company and for energy storage in general.
  • Ahmed knows the Fluence story well through his treasury and investor relations role at AES, where he cultivated strong relationships with investors and financial institutions.
  • He will be a powerful asset for Fluence as we drive growth and achieve our path to profitability.”
    Mr. Nebreda continued, “On behalf of the entire team at Fluence, I would like to thank Manu for his contribution to Fluence.
  • Mr. Sial commented, “I appreciate the opportunity provided by Julian and the Fluence Board of Directors to contribute to Fluence's leadership.